Coronavirus Update: Vaccine Developers Search For Exposed Patients, Celltrion's Infliximab Shows Promise
Despite Hotspots, Recruitment A Major Challenge
As a handful of frontrunners prepare to start Phase III trials of their COVID-19 vaccine candidates, enrolling patients who are likely to be exposed to the virus is of crucial importance.
You may also be interested in...
Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.
BASF enters the lists and a new UK study, CATALYST, gets underway.
Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.